SG11201704427YA - Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal - Google Patents

Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Info

Publication number
SG11201704427YA
SG11201704427YA SG11201704427YA SG11201704427YA SG11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA
Authority
SG
Singapore
Prior art keywords
polypeptides
amino acid
acid sequence
sequence lacking
modified bacteriophage
Prior art date
Application number
SG11201704427YA
Inventor
Rajaraman Krishnan
Eva Asp
Ming Proschitsky
Richard Fisher
Francis J Carr
Robert G E Holgate
Timothy D Jones
Original Assignee
Proclara Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proclara Biosciences Inc filed Critical Proclara Biosciences Inc
Publication of SG11201704427YA publication Critical patent/SG11201704427YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201704427YA 2014-12-03 2015-12-02 Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal SG11201704427YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087052P 2014-12-03 2014-12-03
PCT/US2015/063476 WO2016090022A1 (en) 2014-12-03 2015-12-02 Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Publications (1)

Publication Number Publication Date
SG11201704427YA true SG11201704427YA (en) 2017-06-29

Family

ID=55273507

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704427YA SG11201704427YA (en) 2014-12-03 2015-12-02 Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Country Status (20)

Country Link
US (2) US10722551B2 (en)
EP (1) EP3227313B1 (en)
JP (2) JP6730988B2 (en)
KR (1) KR20170085132A (en)
CN (1) CN107250154A (en)
AR (1) AR102890A1 (en)
AU (1) AU2015358504A1 (en)
BR (1) BR112017011530A2 (en)
CA (1) CA2969128A1 (en)
DK (1) DK3227313T3 (en)
EA (1) EA201791212A1 (en)
ES (1) ES2910017T3 (en)
IL (1) IL252426A0 (en)
MX (1) MX2017007059A (en)
PH (1) PH12017501004A1 (en)
PL (1) PL3227313T3 (en)
PT (1) PT3227313T (en)
SG (1) SG11201704427YA (en)
TW (1) TW201632542A (en)
WO (1) WO2016090022A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093414A (en) 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 Use of P3 of bacteriophage as amyloid binding agents
EA033666B1 (en) 2012-10-02 2019-11-14 Proclara Biosciences Inc Amyloid binding proteins and use thereof
EA030389B1 (en) 2013-05-28 2018-07-31 Проклара Байосайенсиз, Инк. POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE g3p AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
WO2016090022A1 (en) 2014-12-03 2016-06-09 Neurophage Pharmaceuticals, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal
AU2019287623B2 (en) * 2018-06-15 2024-11-07 Amyl Therapeutics Srl General amyloid interaction motif (GAIM)
WO2024119183A1 (en) 2022-12-02 2024-06-06 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DK0417563T3 (en) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-binding proteins
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DK0615451T3 (en) 1992-05-26 2006-04-24 Immunex Corp Hitherto unknown cytokine that binds to CD30
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
DE69934967T2 (en) 1998-12-08 2007-12-06 Biovation Ltd. METHOD FOR REDUCING IMMUNOGENICITY OF PROTEINS
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
BR0207267A (en) 2001-02-19 2004-02-10 Merck Patent Gmbh Artificial proteins with reduced immunogenicity
RU2003129058A (en) 2001-03-08 2005-04-20 Мерк Патент ГмбХ (DE) MODIFIED COLONY-STIMULATING GRANULOSITARY-MACROFAGAL FACTOR (GM-CSF) WITH REDUCED IMMUNOGENITY
DE10238846A1 (en) 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Active fusion proteins and processes for their production
DK1853285T3 (en) 2005-02-01 2011-06-27 Univ Ramot Method of treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
US20090304726A1 (en) 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
BRPI0707871A2 (en) 2006-02-15 2011-05-10 Ramot At Tel Aviv University phage display vehicles, pharmaceutical composition, and methods for treating or inhibiting and diagnosing a brain disease, disorder or condition
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
US20090105090A1 (en) 2006-04-06 2009-04-23 Fumiaki Uchiyama Phage Display By Novel Filamentous Bacteriophage
ATE541038T1 (en) 2006-07-21 2012-01-15 Univ Ramot USE OF A PHAGE DISPLAYING A PEPTIDE OF AN ADHESION PROTEIN FOR THE TREATMENT OF A DISEASE ASSOCIATED WITH INTRACELLULAR FORMATION OF FIBRILLARY PROTEIN INCLUSIONS OR AGGREGATES
KR101485202B1 (en) 2006-10-11 2015-01-22 안티토페 리미티드 T cell epitope databases
WO2009143465A1 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method of imaging abnormal deposits or plaques
BRPI0921557A2 (en) 2008-11-24 2019-09-24 Univ Ramot filamentous bacteriophage, first and second filamentous bacteriophage for use in the treatment of parkinson's disease, pharmaceutical composition, and method for treating a patient
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US8980547B2 (en) 2011-03-11 2015-03-17 Ramot At Tel Aviv University Ltd. Method for treating neurodegenerative tauopathy
CN104093414A (en) 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 Use of P3 of bacteriophage as amyloid binding agents
EA033666B1 (en) 2012-10-02 2019-11-14 Proclara Biosciences Inc Amyloid binding proteins and use thereof
EA030389B1 (en) * 2013-05-28 2018-07-31 Проклара Байосайенсиз, Инк. POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE g3p AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY
WO2016090022A1 (en) 2014-12-03 2016-06-09 Neurophage Pharmaceuticals, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Also Published As

Publication number Publication date
CA2969128A1 (en) 2016-06-09
PL3227313T3 (en) 2022-05-09
ES2910017T3 (en) 2022-05-11
WO2016090022A9 (en) 2016-08-25
WO2016090022A8 (en) 2017-06-22
US11723951B2 (en) 2023-08-15
EP3227313B1 (en) 2022-02-09
JP2017538407A (en) 2017-12-28
US20210015895A1 (en) 2021-01-21
JP6730988B2 (en) 2020-07-29
MX2017007059A (en) 2018-05-02
IL252426A0 (en) 2017-07-31
WO2016090022A1 (en) 2016-06-09
EA201791212A1 (en) 2018-01-31
TW201632542A (en) 2016-09-16
PH12017501004A1 (en) 2017-12-18
DK3227313T3 (en) 2022-04-19
US20180207231A1 (en) 2018-07-26
BR112017011530A2 (en) 2018-03-13
US10722551B2 (en) 2020-07-28
CN107250154A (en) 2017-10-13
EP3227313A1 (en) 2017-10-11
PT3227313T (en) 2022-04-12
AR102890A1 (en) 2017-03-29
JP2020073610A (en) 2020-05-14
AU2015358504A1 (en) 2017-06-29
AU2015358504A8 (en) 2017-07-13
KR20170085132A (en) 2017-07-21

Similar Documents

Publication Publication Date Title
HK1244019A1 (en) Fusion proteins
HK1253684A1 (en) Conditionally active polypeptides
HK1232136A1 (en) P97-ids fusion proteins p97-ids
HK1258877A1 (en) A novel endolysin polypeptide
IL252426A0 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
GB201417652D0 (en) Improved encoding process using a palette mode
HK1231493A1 (en) Pharmaceutically relevant aromatic-cationic peptides
GB201418562D0 (en) Peptides
HK1223285A1 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity g3p
HRP20182029T1 (en) Uti fusion proteins
IL252902A0 (en) Amino acid and peptide conjugates and uses thereof
IL248276A0 (en) Carbohydrate-binding protein
GB201401877D0 (en) Peptides
SG11201606501PA (en) Nanobody-fluorescent protein fusion
HK1253316A1 (en) Peptides
GB2528431B (en) Improved encoding process using a palette mode
GB201713537D0 (en) Fusion Polypeptide
GB201503789D0 (en) Fusion polypeptide
GB201420645D0 (en) Peptides
GB201410686D0 (en) Peptides
GB201409010D0 (en) Peptides
GB201405078D0 (en) Peptides